Aurobindo Pharma’s Unit-IV receives VAI classification from US FDA | Business Upturn

Top Stories

SBI board to consider raising up to $2 billion via public offer, foreign bonds Pidilite Industries Q4 Results: Net profit jumps 36.6% YoY to Rs 584.2 crore, revenue rises 14% Dabur India Q4 Results: Net profit jumps 15.8% YoY to Rs 362 crore, revenue up 7.35% Escorts Kubota Q4 Results: Consolidated net profit flat YoY, margin improves; Rs 33 dividend declared KEI Industries confirms Income Tax searches; says fully cooperating with authorities MRF Q4 Results: Net profit jumps 38%; board approves ₹229 final dividend for FY26 Deal reached to reopen the Strait of Hormuz — Nifty jumps, crude crashes to $92 US and Iran reach agreement on easing blockade in exchange for gradual reopening of Strait of Hormuz: Report SBI board to consider raising up to $2 billion via public offer, foreign bonds Pidilite Industries Q4 Results: Net profit jumps 36.6% YoY to Rs 584.2 crore, revenue rises 14% Dabur India Q4 Results: Net profit jumps 15.8% YoY to Rs 362 crore, revenue up 7.35% Escorts Kubota Q4 Results: Consolidated net profit flat YoY, margin improves; Rs 33 dividend declared KEI Industries confirms Income Tax searches; says fully cooperating with authorities MRF Q4 Results: Net profit jumps 38%; board approves ₹229 final dividend for FY26 Deal reached to reopen the Strait of Hormuz — Nifty jumps, crude crashes to $92 US and Iran reach agreement on easing blockade in exchange for gradual reopening of Strait of Hormuz: Report

HOME /BUSINESS

Aurobindo Pharma’s Unit-IV, part of APL Healthcare Limited, has been classified as ‘Voluntary Action Indicated’ (VAI) by the US FDA, marking the closure of its recent inspection.

The inspection of Unit-IV, located in Andhra Pradesh, was conducted by the United States Food and Drug Administration (US FDA) from December 8 to December 17, 2025. Following the inspection, a ‘Form 483’ was issued with five observations. The recent Establishment Inspection Report (EIR) now categorises the facility as VAI, indicating that the inspection is officially closed.

Disclaimer: This article is based on a regulatory filing submitted to the National Stock Exchange of India (NSE).

Add us as preferred source on Google

TOPICS: Andhra Pradesh APL Healthcare Aurobindo Pharma US FDA